Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

结构性心脏病

  • Home
  • 结构性心脏病
Tricuspid Valve Replacement Outcomes by Baseline Tricuspid Regurgitation Severity: TRISCEND II Trial
Posted inCardiology news

Tricuspid Valve Replacement Outcomes by Baseline Tricuspid Regurgitation Severity: TRISCEND II Trial

Posted by MedXY By MedXY 05/12/2026
TRISCEND II showed that transcatheter tricuspid valve replacement with EVOQUE markedly reduced tricuspid regurgitation and improved clinical outcomes across baseline severity levels, with a stronger signal for benefit in massive or torrential TR.
Read More
  • Laminopathies: Natural History and Risk Prediction of Heart Failure
  • Unveiling the Burden of Valvular Heart Disease Among Older Americans: Insights from the PREVUE-VALVE Study
  • Association of Common Ancestry-Enriched Variants With Cardiomyopathy and Arrhythmias: Insights From Genetic Studies in Individuals of African Ancestry
  • Long-Term Outcomes and Durability of Exceptional Responses to PARP Inhibitors in Recurrent Platinum-Sensitive Ovarian Cancer
  • 3D-Printed Surgical Microscopes: Revolutionizing Microsurgery Training in Resource-Limited Settings
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in